mr PARICK CARROLL

Cited source text

General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act

H.R. 2853

Combating Organized Retail Crime Act of 2025

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

PARADIGM HEALTH INC. via TARPLIN, DOWNS & YOUNG, LLC

Cited source text

General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)

Original LDA source filings (100)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

TOLMAR INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Lobbying related to Medicare policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Source: Senate LDA

Show 96 more cited filings

S. 3822

Break Up Big Medicine Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act

H.R. 1

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)

H.R. 1968

Full-Year Continuing Appropriations and Extensions Act, 2025

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.

H.R. 946

ORPHAN Cures Act

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)

S. 1862

ORPHAN Cures Act

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)

S. 891

Bipartisan Health Care Act

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.

H.R. 10545

American Relief Act, 2025

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 3435 - the Charitable Act S. 566 - the Charitable Act H.R. 10545 American Relief Act of 2025 H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes

H.R. 10545

American Relief Act, 2025

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 8467 - Farm, Food, and National Security Act of 2024 H.R. 10545 - American Relief Act of 2025 Drug safety, prescription drug abuse, value of prescription drugs

H.R. 1826

PSA Screening for HIM Act

Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing

H.R. 1826

PSA Screening for HIM Act

Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing

H.R. 1826

PSA Screening for HIM Act

Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing

H.R. 2550

Special Diabetes Program Reauthorization Act of 2023

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act

H.R. 2872

Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Issues pertaining to NIH appropriations for FY25

H.R. 2872

Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25

H.R. 3435

Charitable Act

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 3435 - the Charitable Act S. 566 - the Charitable Act H.R. 10545 American Relief Act of 2025 H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes

H.R. 3557

American Broadband Deployment Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 3557

American Broadband Deployment Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 3557

American Broadband Deployment Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

State Strategic Stockpile Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

State Strategic Stockpile Act of 2023

Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization

State Strategic Stockpile Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

State Strategic Stockpile Act of 2023

Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization

State Strategic Stockpile Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

State Strategic Stockpile Act of 2023

Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization

H.R. 3837

Improving Public Health Preparedness Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 3837

Improving Public Health Preparedness Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 3837

Improving Public Health Preparedness Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 3916

SCREENS for Cancer Act of 2024

Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED

H.R. 3916

SCREENS for Cancer Act of 2024

Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED

H.R. 405

Essential Medicines Strategic Stockpile Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 405

Essential Medicines Strategic Stockpile Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 405

Essential Medicines Strategic Stockpile Act of 2023

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 4366

Consolidated Appropriations Act, 2024

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25

H.R. 4366

Consolidated Appropriations Act, 2024

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Issues pertaining to NIH appropriations for FY25

H.R. 4421

Preparing for All Hazards and Pathogens Reauthorization Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 4421

Preparing for All Hazards and Pathogens Reauthorization Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 4421

Preparing for All Hazards and Pathogens Reauthorization Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 45

Small Business Tax Fairness and Compliance Simplification Act

Client: THORN RUN PARTNERS (ON BEHALF OF THE PARTNERSHIP TO IMPROVE PATIENT CARE) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.45 - Small Business Tax Fairness and Compliance Simplification Act IRA implementation, patient engagement, alternative payment models

H.R. 4531

Support for Patients and Communities Reauthorization Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 4531

Support for Patients and Communities Reauthorization Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 4531

Support for Patients and Communities Reauthorization Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 4758

Accelerating Kids’ Access to Care Act

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act

H.R. 4818

Treat and Reduce Obesity Act of 2023

Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.4818 - Treat and Reduce Obesity Act of 2023 Medicare & Medicaid payments and coverage issues, Medicare Part D, Medicare Part B, 340B

H.R. 4818

Treat and Reduce Obesity Act of 2023

Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.4818 - Treat and Reduce Obesity Act of 2023 Medicare & Medicaid payments and coverage issues, Medicare Part D, Medicare Part B, 340B

H.R. 4818

Treat and Reduce Obesity Act of 2023

Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.4818 - Treat and Reduce Obesity Act of 2023 Medicare & Medicaid payments and coverage issues, Medicare Part D, Medicare Part B, 340B

H.R. 485

Protecting Health Care for All Patients Act of 2023

Client: THORN RUN PARTNERS (ON BEHALF OF THE PARTNERSHIP TO IMPROVE PATIENT CARE) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.485 - Protecting Health Care for All Patients Act of 2023 IRA implementation, patient engagement, alternative payment models

H.R. 485

Protecting Health Care for All Patients Act of 2023

Client: THORN RUN PARTNERS (ON BEHALF OF THE PARTNERSHIP TO IMPROVE PATIENT CARE) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.485 - Protecting Health Care for All Patients Act of 2023 IRA implementation, patient engagement, alternative payment models

Lower Costs, More Transparency Act

Client: PHRMA · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, supply chain integrity, innovation, 340B, transparency

Lower Costs, More Transparency Act

Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, 340B

Lower Costs, More Transparency Act

Client: ABBVIE INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act 340B, transparency, prescription drug pricing and access, beneficiary access, IRA implementation

Lower Costs, More Transparency Act

Client: BRISTOL MYERS SQUIBB · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act Prescription drug access and affordability, pricing, transparency, biosimilars, 340B

Lower Costs, More Transparency Act

Client: NOVARTIS · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act S.476/H.R. 5547 Maintaining Investments in New Innovation (MINI) Act IRA implementation, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, kidney care policies, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies

Lower Costs, More Transparency Act

Client: MERCK · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, innovation, 340B, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars

Lower Costs, More Transparency Act

Client: BOEHRINGER INGELHEIM · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, prescription drug pricing, prescription drug access and affordability, transparency, 340B

Lower Costs, More Transparency Act

Client: MERCK · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, innovation, 340B, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars

Lower Costs, More Transparency Act

Client: ABBVIE INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act 340B, transparency, prescription drug pricing and access, beneficiary access, IRA implementation

Lower Costs, More Transparency Act

Client: NOVARTIS · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act S.476/H.R. 5547 Maintaining Investments in New Innovation (MINI) Act IRA implementation, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies

Lower Costs, More Transparency Act

Client: BOEHRINGER INGELHEIM · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, prescription drug pricing, prescription drug access and affordability, transparency

Lower Costs, More Transparency Act

Client: NOVARTIS · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act S.476/H.R. 5547 Maintaining Investments in New Innovation (MINI) Act IRA implementation, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies

Lower Costs, More Transparency Act

Client: BRISTOL MYERS SQUIBB · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, prescription drug access and affordability, pricing, transparency, biosimilars, 340B

Lower Costs, More Transparency Act

Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, 340B

Lower Costs, More Transparency Act

Client: BOEHRINGER INGELHEIM · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, prescription drug pricing, prescription drug access and affordability, transparency, 340B

Lower Costs, More Transparency Act

Client: PHRMA · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act IRA implementation, supply chain integrity, innovation, 340B, transparency

H.R. 5547

Maintaining Investments in New Innovation Act

Client: NOVARTIS · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act S.476/H.R. 5547 Maintaining Investments in New Innovation (MINI) Act IRA implementation, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, kidney care policies, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies

H.R. 5547

Maintaining Investments in New Innovation Act

Client: NOVARTIS · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act S.476/H.R. 5547 Maintaining Investments in New Innovation (MINI) Act IRA implementation, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies

H.R. 5547

Maintaining Investments in New Innovation Act

Client: NOVARTIS · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 5378: Lower Costs, More Transparency Act S.476/H.R. 5547 Maintaining Investments in New Innovation (MINI) Act IRA implementation, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies

H.R. 5894

Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 3435 - the Charitable Act S. 566 - the Charitable Act H.R. 10545 American Relief Act of 2025 H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes

H.R. 6992

MAPS Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 6992

MAPS Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 7142

Alternatives to PAIN Act

Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.7142/S.3838 Alternatives to PAIN Act IRA implementation, innovation, health disparities, orphan drugs, 340B, opioid alternative medicine, SUPPORT Act reauthorization

H.R. 7142

Alternatives to PAIN Act

Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.7142/S.3838 Alternatives to PAIN Act IRA implementation, innovation, health disparities, orphan drugs, 340B, opioid alternative medicine, SUPPORT Act reauthorization

H.R. 7463

Extension of Continuing Appropriations and Other Matters Act, 2024

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25

H.R. 7463

Extension of Continuing Appropriations and Other Matters Act, 2024

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Issues pertaining to NIH appropriations for FY25

H.R. 7623

Telehealth Modernization Act of 2024

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

H.R. 766

Dr. Michael C. Burgess Preventive Health Savings Act

Client: FLAGSHIP PIONEERING · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.766/S.114 Preventive Health Savings Act Pandemic preparedness, life science innovation and competitiveness, preemptive health and medicine, biomanufacturing, next generation vaccines and therapeutics, PAPHA reauthorization, AI policy and regulation, AMR research

H.R. 766

Dr. Michael C. Burgess Preventive Health Savings Act

Client: FLAGSHIP PIONEERING · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.766/S.114 Preventive Health Savings Act Pandemic preparedness, life science innovation and competitiveness, preemptive health and medicine, biomanufacturing, next generation vaccines and therapeutics, PAPHA reauthorization, AI policy and regulation, AMR research, rare disease PRV, ag-biotech policy and regulation

H.R. 766

Dr. Michael C. Burgess Preventive Health Savings Act

Client: FLAGSHIP PIONEERING · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.766/S.114 Preventive Health Savings Act Pandemic preparedness, life science innovation and competitiveness, preemptive health and medicine, biomanufacturing, next generation vaccines and therapeutics, PAPHA reauthorization, AI policy and regulation, AMR research

H.R. 8261

Preserving Telehealth, Hospital, and Ambulance Access Act

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

Farm, Food, and National Security Act of 2024

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 8467 - Farm, Food, and National Security Act of 2024 Drug safety, prescription drug abuse, value of prescription drugs, expiring healthcare extenders, access to FDA approved therapies

Farm, Food, and National Security Act of 2024

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 8467 - Farm, Food, and National Security Act of 2024 Drug safety, prescription drug abuse, value of prescription drugs

Farm, Food, and National Security Act of 2024

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.8467 - Farm, Food, and National Security Act of 2024 access to FDA approved therapies

Farm, Food, and National Security Act of 2024

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R. 8467 - Farm, Food, and National Security Act of 2024 H.R. 10545 - American Relief Act of 2025 Drug safety, prescription drug abuse, value of prescription drugs

H.R. 8561

To amend title XVIII of the Social Security Act to address significant under projection of MA local area growth due to wage index reclassification.

Client: EXCELLUS HEALTH PLAN, INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.8561 Medicare Advantage, Medicare reimbursement and payment issues

H.R. 8561

To amend title XVIII of the Social Security Act to address significant under projection of MA local area growth due to wage index reclassification.

Client: EXCELLUS HEALTH PLAN, INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.8561 Medicare Advantage, Medicare reimbursement and payment issues

H.R. 8698

SCREEN for Type 1 Diabetes Act of 2024

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act

H.R. 8698

SCREEN for Type 1 Diabetes Act of 2024

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S.1269 - INSULIN Act of 2023 S.1855 Special Diabetes Program Reauthorization Act of 2023 S.4504/H.R.8698 Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act Issues related to insulin affordability and cell and gene therapies

H.R. 9540

Fight Illicit Pill Presses Act of 2024

Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile

S. 114

Preventive Health Savings Act

Client: FLAGSHIP PIONEERING · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.766/S.114 Preventive Health Savings Act Pandemic preparedness, life science innovation and competitiveness, preemptive health and medicine, biomanufacturing, next generation vaccines and therapeutics, PAPHA reauthorization, AI policy and regulation, AMR research

S. 114

Preventive Health Savings Act

Client: FLAGSHIP PIONEERING · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.766/S.114 Preventive Health Savings Act Pandemic preparedness, life science innovation and competitiveness, preemptive health and medicine, biomanufacturing, next generation vaccines and therapeutics, PAPHA reauthorization, AI policy and regulation, AMR research

S. 114

Preventive Health Savings Act

Client: FLAGSHIP PIONEERING · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.766/S.114 Preventive Health Savings Act Pandemic preparedness, life science innovation and competitiveness, preemptive health and medicine, biomanufacturing, next generation vaccines and therapeutics, PAPHA reauthorization, AI policy and regulation, AMR research, rare disease PRV, ag-biotech policy and regulation

S. 1269

INSULIN Act of 2023

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S.1269 - INSULIN Act of 2023 S.1855 Special Diabetes Program Reauthorization Act of 2023 S.4504/H.R.8698 Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act Issues related to insulin affordability and cell and gene therapies

S. 1269

INSULIN Act of 2023

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act

S. 1269

INSULIN Act of 2023

Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

S. 1269 - INSULIN Act of 2023 S. 1855 Special Diabetes Program Reauthorization Act of 2023 Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act Issues related to insulin affordability

S. 150

Affordable Prescriptions for Patients Act of 2023

Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

Issues related to implementation of Inflation Reduction Act of 2022 (PL 117-169), S. 150, Affordable Prescriptions for Patients Act of 2023

S. 1840

SCREENS for Cancer Act of 2023

Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED

S. 1840

SCREENS for Cancer Act of 2023

Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC

VERTEX PHARMACEUTICALS INCORPORATED via TARPLIN, DOWNS & YOUNG, LLC

Cited source text

H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED

Show 96 more original filings

WHOOP via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Health tech, removal of barrier / maintain existing flexibility to allow access to health tech wellness products

MMM

Medicare/Medicaid

lobbying related to Medicare coverage and health technology

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical and Medicare/Medicaid policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

Federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

VERTANICAL via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

FDA policy

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

UNIQURE BIOPHARMA B.V. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Gene therapy and pharmaceutical policy

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

SAS via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Lobbying related to health care technology and program integrity.

HCR

Health Issues

Lobbying related to health care technology and program integrity.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

SAREPTA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Lobbying related to rare disease policy and coverage

HCR

Health Issues

Lobbying related to rare disease policy

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and Medicare coverage

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

2026 · third_quarter · 3A

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

innovation in rare cancer treatment

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

innovation in rare cancer treatment

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHRMA via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical and Medicare & Medicaid policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

Federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVO NORDISK INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy and access

BUD

Budget/Appropriations

Federal budget issues

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and access

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVARTIS via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

TRD

Trade (domestic/foreign)

Lobbying related to trade

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

Federal budget issues

HCR

Health Issues

Lobbying related to pharmaceutical policy

2026 · third_quarter · Q3

Firm income: $110,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

telehealth, mental health, prescription drug pricing, payment reform

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

IRA, prescription drug pricing, payment reform, innovation

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

MERCK via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Federal budget issues

HCR

Health Issues

IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA

MMM

Medicare/Medicaid

IRA, Medicare and Medicaid payment and coverage issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

JAZZ PHARMACEUTICALS INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of botanical products Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing Expiring healthcare extenders

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

IMMIX BIOPHARMA INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

innovation in rare disease treatment and pharmaceutical policy

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

IDORSIA PHARMACEUTICALS US INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

policies related to the regulation of and access to insomnia treatments

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

PHA

Pharmacy

General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)

HCR

Health Issues

General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act

Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

HANSA BIOPHARMA via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · 3T

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Federal budget issues

HCR

Health Issues

Kidney issues, access to innovation, rare disease issues, organ rejection

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

GENENTECH, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to Medicare & Medicaid and pharmaceutical policy

BUD

Budget/Appropriations

Federal budget issues

HCR

Health Issues

Lobbying related to pharmaceutical policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

FOUNDATION MEDICINE via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to diagnostics and health care policy.

MMM

Medicare/Medicaid

Lobbying related to diagnostics and health care policy and payment issues

TRD

Trade (domestic/foreign)

supply chain

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE

FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech

Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

ELI LILLY AND COMPANY via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Medicare & Medicaid payment and coverage issues, lobbying related to pharmaceutical policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

EXCELLUS HEALTH PLAN, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare Advantage, Medicare reimbursement and payment issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical supply

BUD

Budget/Appropriations

Federal budget issues

MMM

Medicare/Medicaid

lobbying related to Medicare and Medicaid

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

BRISTOL MYERS SQUIBB via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy

MMM

Medicare/Medicaid

Medicare & Medicaid payment and coverage issues

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

BOEHRINGER INGELHEIM via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to Medicare & Medicaid coverage and payment issues

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

Lobbying related to pharmaceutical policy

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

BLUE CROSS BLUE SHIELD ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $110,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

BUD

Budget/Appropriations

federal budget issues

TAX

Taxation/Internal Revenue Code

issues related to tax

MMM

Medicare/Medicaid

Lobbying related to Medicare and Medicaid policy

HCR

Health Issues

BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues

BUD

Budget/Appropriations

Federal budget issues

TAX

Taxation/Internal Revenue Code

Lobbying related to pharmaceutical, tax, and health care policy

TRD

ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $100,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Medicare & Medicaid coverage and reimbursement issues

HCR

Health Issues

Lobbying related to health care policy and research funding

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to health care policy and research funding

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Medicare & Medicaid coverage and reimbursement issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

rare disease and access to innovation

MMM

Medicare/Medicaid

rare disease and access to innovation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

Lobbying related to domestic pharmaceutical supply

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AMGEN INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and Medicare policy

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

Lobbying related to pharmaceutical policy and health care access

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

ASTRAZENECA via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and Medicare and Medicaid policy

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

Lobbying related to pharmaceutical policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to health care policy, access, and coverage

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Lobbying related to health care policy, access and coverage, and Medicare & Medicaid policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ADVAMED via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Lobbying related to medical device policy and Medicare reimbursement/coverage.

HCR

Health Issues

Lobbying related to medical device policy, innovation, technology policy, right to repair and Medicare reimbursement.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ABBOTT (FORMERLY KNOWN AS ALERE INC.) via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

TRD

Trade (domestic/foreign)

issues related to national trade

HCR

Health Issues

Lobbying related to health care policy, Medicare reimbursement

MMM

Medicare/Medicaid

Lobbying related to health care policy, Medicare reimbursement

BUD

ABBVIE INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA

MMM

Medicare/Medicaid

Part B, Part D, drug pricing and access, negotiation,

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

HCR

Health Issues

Lobbying related to pharmaceutical and health care policy

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues

BUD

Budget/Appropriations

Federal budget issues

TAX

HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

PHA

Pharmacy

General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act

ABBVIE INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Part B, Part D, drug pricing and access, negotiation,

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

JAZZ PHARMACEUTICALS INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of botanical products Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing Expiring healthcare extenders

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MERCK via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

IRA, Medicare and Medicaid payment and coverage issues

BUD

Budget/Appropriations

Federal budget issues

HCR

Health Issues

IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVARTIS via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

BUD

Budget/Appropriations

Federal budget issues

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

TRD

Trade (domestic/foreign)

SAS via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Lobbying related to health care technology and program integrity.

HCR

Health Issues

Lobbying related to health care technology and program integrity.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

IDORSIA PHARMACEUTICALS US INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

policies related to the regulation of and access to insomnia treatments

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

IMMIX BIOPHARMA INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

innovation in rare disease treatment and pharmaceutical policy

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

UNIQURE BIOPHARMA B.V. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

innovation in rare cancer treatment

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Gene therapy and pharmaceutical policy

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

VERTANICAL via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

FDA policy

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to health care policy and research funding

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Medicare & Medicaid coverage and reimbursement issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

BLUE CROSS BLUE SHIELD ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $110,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

TAX

Taxation/Internal Revenue Code

issues related to tax

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

Lobbying related to coverage, health insurance policy, and Medicare & Medicaid policy

MMM

Medicare/Medicaid

BRISTOL MYERS SQUIBB via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Medicare & Medicaid payment and coverage issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

PHRMA via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · 2A

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical and Medicare & Medicaid policy

BUD

Budget/Appropriations

Federal budget issues

HCR

Health Issues

Lobbying related to pharmaceutical policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

PHRMA via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical and Medicare & Medicaid policy

BUD

Budget/Appropriations

Federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

EXCELLUS HEALTH PLAN, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare Advantage, Medicare reimbursement and payment issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NOVO NORDISK INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Federal budget issues

HCR

Health Issues

Lobbying related to pharmaceutical policy and access

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and access

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

WHOOP via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Health tech, removal of barrier / maintain existing flexibility to allow access to health tech wellness products

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

SAREPTA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to rare disease policy

MMM

Medicare/Medicaid

Lobbying related to rare disease policy and coverage

BUD

Budget/Appropriations

federal budget issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and Medicare coverage

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $110,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

telehealth, mental health, prescription drug pricing, payment reform

HCR

Health Issues

IRA, prescription drug pricing, payment reform, innovation

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HANSA BIOPHARMA via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Kidney issues, access to innovation, rare disease issues, organ rejection

BUD

Budget/Appropriations

Federal budget issues

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

GENENTECH, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Federal budget issues

MMM

Medicare/Medicaid

Lobbying related to Medicare & Medicaid and pharmaceutical policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ELI LILLY AND COMPANY via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Medicare & Medicaid payment and coverage issues, lobbying related to pharmaceutical policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $16,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Lobbying related to pharmaceutical supply

BUD

Budget/Appropriations

Federal budget issues

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

BOEHRINGER INGELHEIM via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Lobbying related to pharmaceutical policy

MMM

Medicare/Medicaid

Lobbying related to Medicare & Medicaid coverage and payment issues

BUD

Budget/Appropriations

federal budget issues

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ASTRAZENECA via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and Medicare and Medicaid policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

rare disease and access to innovation

HCR

Health Issues

rare disease and access to innovation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AMGEN INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical policy and Medicare policy

HCR

Health Issues

Lobbying related to pharmaceutical policy and health care access

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

ADVAMED via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Lobbying related to medical device policy, innovation, and Medicare reimbursement.

MMM

Medicare/Medicaid

Lobbying related to medical device policy and Medicare reimbursement/coverage.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Lobbying related to health care policy, access and coverage, and Medicare & Medicaid policy

HCR

Health Issues

Lobbying related to health care policy, access, and coverage

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ABBOTT (FORMERLY KNOWN AS ALERE INC.) via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

BUD

Budget/Appropriations

federal budget issues

MMM

Medicare/Medicaid

Lobbying related to health care policy, Medicare reimbursement

TRD

Trade (domestic/foreign)

issues related to national trade

HCR

Health Issues

AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Lobbying related to domestic pharmaceutical supply

BUD

Budget/Appropriations

federal budget issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

VERTEX PHARMACEUTICALS INCORPORATED via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Lobbying related to pharmaceutical and Medicare/Medicaid policy

HCR

Health Issues

Lobbying related to pharmaceutical policy

BUD

Budget/Appropriations

Federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

FOUNDATION MEDICINE via TARPLIN, DOWNS & YOUNG, LLC

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TRD

Trade (domestic/foreign)

supply chain

HCR

Health Issues

Lobbying related to diagnostics and health care policy.

MMM

Medicare/Medicaid

Lobbying related to diagnostics and health care policy and payment issues

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE

IMMIX BIOPHARMA INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

innovation in rare disease treatment

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

IMMIX BIOPHARMA INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

innovation in rare disease treatment

UNIQURE BIOPHARMA B.V. via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Gene therapy

Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

BLUE CROSS BLUE SHIELD ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $110,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

telehealth, coverage, health savings accounts, transparency

MMM

Medicare/Medicaid

Medicare & Medicaid payment and coverage issues, Medicare Advantage

TAX

Taxation/Internal Revenue Code

NOVO NORDISK INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

Federal budget issues

MMM

Medicare/Medicaid

Treat and Reduce Obesity Act, obesity treatment

HCR

Health Issues

IRA, medication affordability and access, general diabetes prevention, obesity, impacts of drug shortages, drug supply chain

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

SAS via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

program integrity and technology reform, FDA modernization

MMM

Medicare/Medicaid

IRA, medical review pilot, data use by Medicare Administrative Contractors, program integrity and technology reform

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

BRISTOL MYERS SQUIBB via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

BUD

Budget/Appropriations

federal budget issues

HCR

Health Issues

prescription drug access and affordability, pricing, transparency, drug pricing in federal programs

MMM

Medicare/Medicaid

IRA, Medicare & Medicaid payment and coverage issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

VERTEX PHARMACEUTICALS INCORPORATED via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, drug pricing in federal programs, opioid alternative medicines, awareness of rare kidney disorders

MMM

Medicare/Medicaid

Medicare & Medicaid payment and coverage issues

BUD

Budget/Appropriations

Federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization

MMM

Medicare/Medicaid

Medicare & Medicaid payment and coverage issues

BUD

Budget/Appropriations

federal budget issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

ADVAMED via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Medicare coverage regulation and reimbursement of imaging services, Medicare physician payment, equipment maintenance, coding, HOPPS, E&M codes/budget neutrality, AI coverage and reimbursement

HCR

Health Issues

imaging policy, device regulation, innovation, coverage decisions, AI, device shortages, device servicing and manufacturing

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

rare disease and access to innovation

MMM

Medicare/Medicaid

rare disease and access to innovation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

IDORSIA PHARMACEUTICALS US INC via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

policies related to the regulation of and access to insomnia treatments

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

JAZZ PHARMACEUTICALS INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of botanical products Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing Expiring healthcare extenders ORPHAN Cures

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

JAZZ PHARMACEUTICALS INC. via TARPLIN, DOWNS & YOUNG, LLC

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Regulation of botanical products Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing Expiring healthcare extenders Issues related to BIOSECURE

Filing targets: HOUSE OF REPRESENTATIVES, SENATE